exemestane

(redirected from Aromasin)
Also found in: Medical.
Translations

exemestane

n exemestano
References in periodicals archive ?
The company said it recently received Food and Drug Administration approval for the product, a generic version of Aromasin from Pfizer Inc.
Exemestane Tablets are equivalent (ABrated) to the branded product, Aromasin.
M2 PHARMA-October 12, 2017-Upsher-Smith unveils generic Aromasin (Exemestane) Tablet in the US
M2 EQUITYBITES-October 12, 2017-Upsher-Smith unveils generic Aromasin (Exemestane) Tablet in the US
For postmenopausal women who take tamoxifen and/or aromatase inhibitors (Arimidex, Aromasin, Femara) in order to prevent a cancer recurrence, a 10-year course of treatment is now a typical recommendation, rather than the previously recommended 5-year period.
The global breast cancer therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes - brand name (chemical name) such as antimetabolites - Gemzar (gemcitabine), aromatase inhibitors - Afinitor (everolimus), Arimidex (anastrozole), Aromasin (exemestane), Femara (leterozole), Ibrance (palbociclib); Her2 Inhibitors - Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine), Perjeta (pertuzumab), Tykerb (lapatinib); Hormone receptors - Fareston, Faslodex, Zoladex; and Mitotic inhibitors - Halaven (eribulin), Ixempra (ixabepilone), Taxotere (docetaxel), and forecasts growth trends (CAGR% - 2016 to 2020).
According to the NOV the FDA issued to Pfizer in 2009, one of Pfizer's sponsored links provided incomplete content about dosage information for their product Aromasin.
Table 1: Metabolism and Transport Effects (10-13) Arimidex Aromasin Femara Tamoxifen CYP1A2 weakly inhibits CYP2A6 minor substrate minor weakly substrate inhibits weakly inhibits CYP3A4 weakly major substrate minor major substrate inhibits weakly induces substrate weakly inhibits CYP2B6 minor substrate weakly inhibits CYP2C8 weakly weakly inhibits inhibits CYP2C9 weakly major substrate inhibits weakly inhibits CYP2C19 weakly inhibits CYP2D6 major substrate CYP2E1 minor substrate + minor substrate ++ major substrate [down arrow] weakly inhibits [down arrow] [down arrow] strongly induces [up arrow] weakly inhibits
ISLAMABAD -- In what may be seen as a positive development, it has emerged that the anti-estrogen drug Aromasin reduces the risk of breast cancer recurrence by about one-third in postmenopausal women previously treated with tamoxifen.
Aromatase inhibitors (Arimidex, Aromasin, or Femara) have fewer side effects and more benefits than tamoxifen.
Exemestane is marketed as Aromasin by its maker Pfizer, which funded the study.
s (New York) breast-cancer drug Aromasin and similar treatments from AstraZeneca Plc (London GBR) and Novartis AG (Basel CHE) make women 26% more likely to develop heart disease than an older therapy, a study found.